Androvia LifeSciences to Present Clinical Data Demonstrating Capability of Cap-Score™ Sperm Function Test for Fertility Evaluation At 42nd Annual Conference of the American Society of Andrology (ASA)
MOUNTAINSIDE, N.J., April 20, 2017 /PRNewswire/ -- Androvia LifeSciences today announced that data related to the company's proprietary technology, the Cap-ScoreTM Sperm Function Test, will be presented in an oral session at the 42nd Annual Conference of the American Society of Andrology (ASA), to be held April 22 – 25, 2017 in Miami, Florida. An additional study related to the technology will be presented in a poster session. A laboratory developed test, the Cap-Score Sperm Function Test, is the only assay that can determine if sperm can capacitate, indicating the percentage of sperm that can actually fertilize an egg, and comparing each man's results to a normal, fertile population.
The data being presented at the ASA annual conference this year are:
Localization patterns of the ganglioside GM1 identify sperm capable of undergoing capacitation and acrosome exocytosis.
- Presenter: Alexander J. Travis, PhD, associate professor, Cornell University and chief scientific officer, Androvia LifeSciences
- Oral Presentation: Tuesday, April 25, 2017 at 11:15 am Eastern Daylight Time (EDT)
Lipid regulation of sperm function: from basic sciences to a clinical test of male fertility
- Presenter: Alexander J. Travis, PhD, associate professor, Cornell University and chief scientific officer, Androvia LifeSciences
- Abstract #136, Poster session II: Monday, April 24, 2017, 11:15 am – 12:30 pm EDT
Abstracts summarizing these data are published on the ASA website and are available to conference registrants and ASA members at: http://onlinelibrary.wiley.com/doi/10.1111/andr.2017.5.issue-S1/issuetoc#content.
These data come on the heels of the publication of two papers presenting clinical and technology validation studies in the journal Molecular Reproduction and Development, a Wiley publication. The two papers, provide scientific evidence of the clinical utility and value of this technology, the Cap-Score Sperm Function Test.
Infertility
Approximately 73 million couples experience infertility globally. At least 6.7 million infertile couples live in the United States. Male factor infertility contributes to roughly half of all cases of infertility, and 50% of male infertility cases are unexplained by traditional semen analysis.
About Cap-Score Sperm Function Test
A laboratory-developed test designed to assess and measure the fertilizing ability of sperm, to help couples and reproductive health care professionals make informed decisions about the fertility solution that is best suited for that couple. The Cap-Score Sperm Function Test provides an analysis of the sperm on a molecular level, and is the only assay that evaluates capacitation, the process by which sperm acquire the ability to fertilize an egg. The test is designed to complement the traditional semen analysis which determines sperm count, motility and appearance.
About Androvia LifeSciences
Located in Mountainside, NJ, Androvia LifeSciences is a CLIA registered laboratory. The company's first product, the Cap-Score SFT, has been developed to empower couples and clinicians with critical information, helping them to achieve more personalized fertility solutions. For more information on Androvia and the Cap-Score SFT please visit www.androvialifesciences.com.
SOURCE Androvia LifeSciences
Share this article